Press release 📈 Stocks 🌍 United States

Sino Biological Launches 4RISE High-Throughput Wet-Lab Validation Service

Sino Biological debuts 4RISE, a new wet-lab validation service for AI-designed protein binders that provides expression in 3 hours and binding data within 3 days to speed up drug discovery cycles.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: 301047.SZ → 2/10 (60% confidence).

📊 Affected Assets (1)

301047.SZ
Neutral 🤖 60%
📅 Short-term 🌍 CN · Explicit

Sino Biological launches 4RISE, a new wet-lab validation service for AI-designed protein binders with 3-hour cell-free expression and binding data in 3 days. This is a product launch without revenue figures, contract values or guidance changes, so it does not materially alter the financial outlook. The cited publication track record and claims like over 99% expression success are marketing, not quantified financial impact.

Catalysts
  • • Launch of 4RISE high-throughput wet-lab validation services announced on 13 November 2026
Risk Factors
  • • No financial figures, order values or revenue guidance given in the announcement

🧭 Full analysis of these assets

🎯 Key Takeaways

  • Sino Biological's XPressMAX platform achieves protein synthesis in 3 hours with over 99% expression success rates.
  • The 4RISE service provides AI-ready binding data in 3 days using high-throughput SPR and BLI technologies.
  • The platform includes over 20 development assays, 1,000 protein bioactivity assays, and 10 cell-based functional assays for candidate evaluation.

📝 Executive Summary

Sino Biological (301047.SZ) has introduced 4RISE, a high-throughput wet-lab service designed to accelerate AI-driven protein binder research. The platform utilizes the company's XPressMAX cell-free protein synthesis technology to deliver binding data in as little as 3 days, supporting researchers with real-time API access to structured experimental results.

❓ FAQ

Does this product launch change Sino Biological's earnings outlook?

The announcement contains no revenue figures, contracts or guidance, so the financial outlook cannot be assessed from it.